Takai E, Yachida S. Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol 2015; 7(10): 250-258 [PMID: 26483879 DOI: 10.4251/wjgo.v7.i10.250]
Corresponding Author of This Article
Erina Takai, PhD, Division of Cancer Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ertakai@ncc.go.jp
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2015; 7(10): 250-258 Published online Oct 15, 2015. doi: 10.4251/wjgo.v7.i10.250
Genomic alterations in pancreatic cancer and their relevance to therapy
Erina Takai, Shinichi Yachida
Erina Takai, Shinichi Yachida, Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Author contributions: Takai E performed the majority of the writing and prepared the figure; Yachida S designed the outline and supervised the writing of the paper.
Supported by Grants-in Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, No. 26870874 to Takai E and No. 25134719 to Yachida S; the National Cancer Center Research and Development Fund (25-A-3 to Takai E and Yachida S); the Takeda Science Foundation (Yachida S); the Uehara Memorial Foundation (Yachida S); the Mochida Memorial Foundation for Medical and Pharmaceutical Research (Yachida S); the Medical Research Encouragement Prize of the Japan Medical Association (Yachida S); the Pancreas Research Foundation of Japan (Yachida S); Princess Takamatsu Cancer Research Fund (Yachida S).
Conflict-of-interest statement: There is no conflict of interest associated with any of the authors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Erina Takai, PhD, Division of Cancer Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. ertakai@ncc.go.jp
Telephone: +81-3-35422511 Fax: +81-3-35453567
Received: May 1, 2015 Peer-review started: May 8, 2015 First decision: July 17, 2015 Revised: July 28, 2015 Accepted: September 10, 2015 Article in press: September 16, 2015 Published online: October 15, 2015
Abstract
Pancreatic cancer is a highly lethal cancer type, for which there are few viable therapeutic options. But, with the advance of sequencing technologies for global genomic analysis, the landscape of genomic alterations in pancreatic cancer is becoming increasingly well understood. In this review, we summarize current knowledge of genomic alterations in 12 core signaling pathways or cellular processes in pancreatic ductal adenocarcinoma, which is the most common type of malignancy in the pancreas, including four commonly mutated genes and many other genes that are mutated at low frequencies. We also describe the potential implications of these genomic alterations for development of novel therapeutic approaches in the context of personalized medicine.
Core tip: With the advance of sequencing technologies for global genomic analysis, the landscape of genomic alterations in pancreatic cancer is becoming increasingly well understood. In this review, we summarize the latest knowledge of genomic alterations in pancreatic ductal adenocarcinoma including commonly mutated genes and many other genes that are mutated at low frequencies. We also describe the potential implications of these genomic alterations for development of novel therapeutic approaches in the context of personalized medicine.
